Study Conduct

ACRES, BSI collaborate on clinical research sites standards

Tuesday, December 13, 2016

The Alliance for Clinical Research Excellence and Safety (ACRES), in partnership with the British Standards Institution (BSI), has launched a multi-stakeholder global working party to fast-track development of standards for all aspects of site work, laying the foundation for recognizing and rewarding excellence at clinical research sites worldwide and accelerating development of safe and effective new medicines.

[Read More]

Center Point Clinical Services launches site-less CRO

Thursday, December 8, 2016

Center Point Clinical Services, creator of the Clinical Trial Research Pharmacist (CTRP) solution, has launched the world’s first site-less technology CRO. The site-less CRO model is designed to support the evolving world of clinical trials by empowering study sponsors to de-risk the clinical trial process, increase quality, reduce costs and ensure robust data for regulatory submissions.

[Read More]

Report: Vast swathes of human biology untouched by drug discovery programs

Monday, December 5, 2016

Scientists have created a map of all 1,578 licensed drugs and their mechanisms of action—as a means of identifying ‘uncharted waters’ in the search for future treatments. Their analysis of drugs licensed through the FDA reveals that 667 separate proteins in the human body have had drugs developed against them—just an estimated 3.5% of the 20,000 human proteins.

[Read More]

Report: Clinical research benefits the U.K. economy

Friday, December 2, 2016

An independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network and produced by KPMG’s Economics team, provides an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the U.K. The report includes assessment of the economic contribution made to the U.K. economy through clinical research activity supported by the network; analysis to quantify the value of payments made to NHS Trusts for commercial studies, and the value to the NHS of pharmaceuticals used as part of industry-sponsored studies.

[Read More]